TNYAHIGH SIGNALFINANCIAL10-K

TNYA experienced a dramatic cash infusion increasing from $4.3M to $100.5M while significantly improving operational metrics across R&D spending, operating losses, and cash burn.

This massive 2,226% increase in cash suggests a major financing event that has dramatically strengthened TNYA's financial position and extended their runway for clinical development. The company has simultaneously improved operational efficiency by reducing R&D expenses 21% while maintaining their Phase 1b/2 trials for both TN-201 and TN-401, suggesting better capital allocation and cost management.

Comparing 2026-03-11 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

TNYA's financial profile transformed dramatically with cash increasing from $4.3M to $100.5M, likely from a major equity raise that boosted stockholders' equity 33% and total assets 23%. Operating performance improved significantly with R&D expenses declining 21% and operating losses narrowing from -$115.9M to -$93.3M, while operating cash flow improved 25% to -$68.3M. This combination of substantial new capital and improved operational efficiency positions the company with a much stronger balance sheet and extended runway to advance their gene therapy pipeline through clinical development.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+2225.9%
$4.3M→$100.5M

Cash position surged 2225.9% — strong cash generation or capital raise providing significant financial cushion.

Share Buybacks
Cash Flow
+1200%
$1K→$13K

Share repurchases increased 1200% — management returning capital, signals confidence in intrinsic value.

Current Assets
Balance Sheet
+56.7%
$67.4M→$105.6M

Current assets grew 56.7% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-39.7%
$1.0M→$618K

Capex reduced 39.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
+32.8%
$92.9M→$123.3M

Equity base grew 32.8% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Cash Flow
Cash Flow
+24.6%
-$90.5M→-$68.3M

Operating cash flow grew 24.6% — strong conversion of earnings to cash, healthy business fundamentals.

Total Assets
Balance Sheet
+22.5%
$119.9M→$146.9M

Asset base grew 22.5% — expansion through organic growth, acquisitions, or capital deployment.

R&D Expense
P&L
-20.9%
$86.7M→$68.6M

R&D spending cut 20.9% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+19.5%
-$115.9M→-$93.3M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Net Income
P&L
+18.5%
-$111.1M→-$90.6M

Net income grew 18.5% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-11
PRIOR — 2025-03-10
ADDED
Heart disease remains the leading cause of death in the world.
In the U.S., one person dies from a cardiovascular-related health condition every 34 seconds, a gruesome statistic that translates to one in every three deaths in the U.S each year.
One in 20 adults suffer from congenital heart disease (CHD) and the picture is equally bleak at the other end of the age spectrum, as approximately 40,000 children are born in the U.S every year with CHD, the leading cause of birth defect-related morbidity and mortality.
We are primarily focused on advancing our clinical-stage gene therapy candidates, TN-201, for MYBPC3 -associated hypertrophic cardiomyopathy (HCM), and TN-401, for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Each candidate is currently in Phase 1b/2 clinical testing to establish the safety and efficacy profile of two different doses.
+7 more — sign up free →
REMOVED
In the U.S., one in every five deaths is attributable to heart disease, and an estimated 40,000 infants are born each year with congenital heart conditions.
We are primarily focused on advancing our lead investigational product candidates, TN-201, a gene therapy for MYBPC3 -associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2 -associated arrhythmogenic right ventricular cardiomyopathy (ARVC).
Each candidate is currently in clinical testing to establish the safety profile of two different doses in adults with disease due to pathogenic/likely pathogenic mutations.
We anticipate that data generated in the next year will inform late-stage development by characterizing each candidates safety and tolerability profile, ability to transduce target heart cells, and produce the lacking protein underlying disease to slow or even halt disease progression.
Early on in our company history, we invested in differentiated capabilities to enable modality agnostic target identification, validation, anchored in human genetics and the use of human disease models.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →